The Promoter Hypermethylation of SULT2B1 Accelerates Esophagus Tumorigenesis Via Downregulated PER1

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2021 Nov 3

PMID 34730281

Citations 8

Authors

Zhuo Li

Meng-Yan Li

Ling-Ling Wang

Lei Li

Qing-Yun Chen

Ying-Hui Zhu

Yan Li

Yan-Ru Qin

Xin-Yuan Guan

Affiliations

Soon will be listed here.

Abstract

Background: Esophageal cancer is currently the eighth most common tumor in the world and a leading cause of cancer death. SULT2B1 plays crucial roles in tumorigenesis. The purpose of this study is to explore the role of SULT2B1 in esophageal squamous cell carcinoma (ESCC).

Methods: The expression of SULT2B1 and its clinicopathological characteristics were evaluated in ESCC cohorts. Bisulfite genomic sequencing and methylation specific PCR were used to detect the promoter hypermethylation of the SULT2B1 gene. The effects of SULT2B1 on the biological characters of ESCC cells were identified on functional assays. Subcutaneous xenograft models revealed the role of SULT2B1 in vivo with tumor growth. RNA-Seq analysis and qRT-PCR were performed to recognize the targeted effect of SULT2B1 on PER1.

Results: SULT2B1 was not expressed or at a low level in most patients with ESCC or in ESCC cell lines, and this was accompanied by poor clinical prognosis. Furthermore, the downregulation of SULT2B1 occurred in promoter hypermethylation. According to the functional results, overexpression of SULT2B1 could inhibit tumoral proliferation in vitro and retard tumor growth in vivo, whereas SULT2B1 knockdown could accelerate ESCC progression. Mechanistically, SULT2B1 targeted PER1 at the mRNA level during post-transcriptional regulation. Finally, PER1 was verified as a suppressor and poor-prognosis factor in ESCC.

Conclusions: SULT2B1 loss is a consequence owing to its ability to promote hypermethylation. In addition, it serves as a suppressor and poor-prognosis factor because of the post-transcriptional regulation of PER1 in ESCC.

Citing Articles

SULT2B1: a novel therapeutic target in colorectal cancer via modulation of AKT/PKM2-mediated glycolysis and proliferation.

Ma J, Sun F, Li W, Du R, Liu M, Wei Q J Transl Med. 2024; 22(1):1093.

PMID: 39623433 PMC: 11613740. DOI: 10.1186/s12967-024-05910-4.

Human sulfotransferase physiological role and the impact of genetic polymorphism on enzyme activity and pathological conditions.

Alherz F Front Genet. 2024; 15:1464243.

PMID: 39280099 PMC: 11392796. DOI: 10.3389/fgene.2024.1464243.

Sulfotransferase SULT2B1 facilitates colon cancer metastasis by promoting SCD1-mediated lipid metabolism.

Che G, Wang W, Wang J, He C, Yin J, Chen Z Clin Transl Med. 2024; 14(2):e1587.

PMID: 38372484 PMC: 10875708. DOI: 10.1002/ctm2.1587.

Complex roles for sulfation in the toxicities of polychlorinated biphenyls.

Duffel M, Lehmler H Crit Rev Toxicol. 2024; 54(2):92-122.

PMID: 38363552 PMC: 11067068. DOI: 10.1080/10408444.2024.2311270.

Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma.

An L, Li M, Jia Q Mol Cancer. 2023; 22(1):140.

PMID: 37598158 PMC: 10439611. DOI: 10.1186/s12943-023-01839-2.

References

He D, Falany C . Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells. Prostate. 2007; 67(12):1318-29. DOI: 10.1002/pros.20615. View

Dobrovic A, Kristensen L . DNA methylation, epimutations and cancer predisposition. Int J Biochem Cell Biol. 2008; 41(1):34-9. DOI: 10.1016/j.biocel.2008.09.006. View

Meloche C, Falany C . Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001; 77(4-5):261-9. DOI: 10.1016/s0960-0760(01)00064-4. View

Kettner N, Voicu H, Finegold M, Coarfa C, Sreekumar A, Putluri N . Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis. Cancer Cell. 2016; 30(6):909-924. PMC: 5695235. DOI: 10.1016/j.ccell.2016.10.007. View

Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T . Characterization of 21 newly established esophageal cancer cell lines. Cancer. 1992; 69(2):277-84. DOI: 10.1002/1097-0142(19920115)69:2<277::aid-cncr2820690202>3.0.co;2-c. View

Deng F, Yang K . Current Status of Research on the Period Family of Clock Genes in the Occurrence and Development of Cancer. J Cancer. 2019; 10(5):1117-1123. PMC: 6400694. DOI: 10.7150/jca.29212. View

Sahar S, Sassone-Corsi P . Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009; 9(12):886-96. DOI: 10.1038/nrc2747. View

Jones J, McMahon D . The core clock gene Per1 phases molecular and electrical circadian rhythms in SCN neurons. PeerJ. 2016; 4:e2297. PMC: 4991845. DOI: 10.7717/peerj.2297. View

Yang G, Yang Y, Tang H, Yang K . Loss of the clock gene Per1 promotes oral squamous cell carcinoma progression via the AKT/mTOR pathway. Cancer Sci. 2020; 111(5):1542-1554. PMC: 7226219. DOI: 10.1111/cas.14362. View

10.

Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R . Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 2014; 13(20):3282-91. PMC: 4613905. DOI: 10.4161/15384101.2014.954454. View

11.

Mikeska T, Bock C, Do H, Dobrovic A . DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn. 2012; 12(5):473-87. DOI: 10.1586/erm.12.45. View

12.

Yin L, Chen G . Verteporfin Promotes the Apoptosis and Inhibits the Proliferation, Migration, and Invasion of Cervical Cancer Cells by Downregulating SULT2B1 Expression. Med Sci Monit. 2020; 26:e926780. PMC: 7586758. DOI: 10.12659/MSM.926780. View

13.

Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J . A role for the clock gene per1 in prostate cancer. Cancer Res. 2009; 69(19):7619-25. PMC: 2756309. DOI: 10.1158/0008-5472.CAN-08-4199. View

14.

Li Y, Chen L, Nie C, Zeng T, Liu H, Mao X . Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma. Cancer Res. 2011; 71(19):6106-15. DOI: 10.1158/0008-5472.CAN-10-4291. View

15.

Mostafaie N, Kallay E, Sauerzapf E, Bonner E, Kriwanek S, Cross H . Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog. 2009; 48(7):642-7. DOI: 10.1002/mc.20510. View

16.

Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler H . The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006; 22(3):375-82. DOI: 10.1016/j.molcel.2006.03.038. View

17.

Wheeler J, Reed C . Epidemiology of esophageal cancer. Surg Clin North Am. 2012; 92(5):1077-87. DOI: 10.1016/j.suc.2012.07.008. View

18.

Bieche I, Girault I, Urbain E, Tozlu S, Lidereau R . Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res. 2004; 6(3):R252-63. PMC: 400681. DOI: 10.1186/bcr784. View

19.

Yang X, Xu Y, Guo F, Ning Y, Zhi X, Yin L . Hydroxysteroid sulfotransferase SULT2B1b promotes hepatocellular carcinoma cells proliferation in vitro and in vivo. PLoS One. 2013; 8(4):e60853. PMC: 3623875. DOI: 10.1371/journal.pone.0060853. View

20.

Liu B, Xu K, Jiang Y, Li X . Aberrant expression of Per1, Per2 and Per3 and their prognostic relevance in non-small cell lung cancer. Int J Clin Exp Pathol. 2015; 7(11):7863-71. PMC: 4270614. View